Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Digital health : patient safety and the next frontier
Medical and wearable devices, remote in-vitro diagnostics and digital therapeutic products - the rapidly evolving world of digital health is bringing more and more devices into patients’ hands. But along with the benefits, there are safety considerations for people and data.
-
ICON at SCDM 2024: Connecting the dots of clinical data management
Four ICON experts shared insights at the 2024 Society for Clinical Data Management conference across topics of RBQM, change management, data managers and diversity.
-
Navigating regulatory landscapes: A guide to global submission standards
This blog summarises the key insights and recommendations from our recent webinar, offering a guide for pharmaceutical stakeholders navigating the complex terrain of regulatory submissions.
-
Integrating Performance Studies of In-Vitro Diagnostics into Clinical Trials: A Complex Challenge
Integrating performance studies of IVDs within clinical trials is a complex yet essential endeavour in advancing healthcare innovation. We explore how to navigate the nuances of regulations and embrace collaborative initiatives to overcome challenges and unlock the full potential of combined trials.
-
SDoH data analysis for proactive outcome improvement: A multilayered approach
Social determinants of health affect patients in widely variable ways, and proper, multi-layered analysis is required to gain actionable insight into patient healthcare consumption and behaviour to optimise brand strategy and deliver better solutions and services to patients.
-
Navigating the complexities of healthcare data types
Navigating the landscape of healthcare data has become increasingly challenging amidst a multitude of data types including open and closed claims sets. Choosing the appropriate foundational dataset will empower data-driven solutions to your business questions.
-
Cross-border initiative to empower rare disease researchers
ICON joins new EU initiative to boost cross-border collaboration.
-
How AI could transform literature surveillance for pharmacovigilance
In pharmacovigilance AI could be used to detect adverse events sooner, offering benefits for patients and researchers.
-
Complexities of running clinical trials in retinal disorders and ways to overcome them
In this blog, we will explore the complexities of running clinical trials in retinal disorders and discuss ways to overcome these challenges based on our experiences from running multiple global retina studies in various indications.
-
SDoH data for efficient, patient-centred clinical trials
The social determinants of health (SDoH) are a key component of understanding and delivering better outcomes for patients.
-
.png?crop=yes&w=210&h=209&itok=QiYhD-ZE "phuse-blog-_Mega Drop Down (MDD).png")
Insights from PHUSE US Connect 2024
ICON recently attended the PHUSE US Connect Conference, which took place from February 25th to 28th in Bethesda, Maryland, participating in exhibitions, unique presentations and interactive discussions on key topics. ICON’s experts shared their insights in multiple presentations within the statistical programming sphere.
-
Diabesity: Overlapping pathophysiology informs multi-indication treatment
As recognition of the overlap between obesity and diabetes has grown, so have efforts to develop treatments that can treat the two conditions in tandem.
-
Site Training for Clinical Trial Success
Training site staff on clinical trial protocols takes time and money, and poor training modules can lead to low compliance or staff that is technically trained, but have missed the learning objectives. Effective training using rich and varied content, leveraging highly engaging methodology and comprehension checks will provide learners with confidence and retention long after the training is completed. Learn more about what you need to reduce risk, increase compliance and enhance quality with a comprehensive training solution.
-
Beyond awareness: Driving progress on the Rare Disease journey
ICON employees share their experience with Rare Diseases.
-
Rare disease trials require effective participation support strategies to succeed
ICON is leading the way in rare disease clinical research having supported 778 rare disease clinical trials in the past five years. Every day, thousands of colleagues at ICON work tirelessly to support the success of rare disease clinical research – because patients can’t wait.
-
Strategies for de-risking rare disease programmes during research and development
Difficulties in research and development for rare disease therapeutics have been compounded by a historically challenging market for biotechs. ICON experts share how biotechs can maximise funding for rare disease therapeutic development in our blog.
-
Insights from the 2024 ISCR Annual Conference: India’s evolving clinical research arena
ICON participated in the 17th annual Indian Society for Clinical Research (ISCR) conference on the 1-3 February in Hyderabad, India. ICON experts shared insights on topics of special interest including clinical data management and biostatistics and statistical programming, among others.
-
-420x250.jpg?crop=yes&w=210&h=209&itok=Rf8XyAT4 "(10708-PV-Affiliate-Model-Whitepaper)-420x250.jpg")
Ensuring safety and compliance: The essentials of outsourcing pharmacovigilance
In this blog, we delve into the rationale behind outsourcing pharmacovigilance activities at the affiliate level and explore the essential requirements for appointing local persons for pharmacovigilance (LPPVs).
-
Looking forward: The most significant 2024 US healthcare trends - Part 5 of 5
When discussing the 5 biggest challenges that await the healthcare industry in 2024, US politics is a key issue. America is clearly divided on many issues, including those involving government spending, healthcare reimbursements, and treatment coverage issues.
-
Looking forward: The most significant 2024 US healthcare trends—Part 4 of 5
Given that some of the overall physical- and mental-health indicators show negative progress even while healthcare costs are rising, it begs the question: What is the reason for the backslide?